26 November 2020 - Afamelanotide acetate (Scenesse) was approved on 22 October 2020.

Scenesse is indicated for prevention of phototoxicity in adult patients with erythropoietic protoporphyria.

The sponsor of Scenesse is Melbourne based Clinuvel Pharmaceuticals

Read Australian prescription medicine decision summary for afamelanotide acetate